Stay updated with breaking news from Nexalin Gen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HOUSTON, TX, June 13, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that its second generation (Gen-2), 15 milliamp (mA) neurostimulation device
The FDA has agreed on the design for Nexalin's planned clinical studies of the Gen-3 HALO Clarity, targeting insomnia and anxiety.
HOUSTON, TX, May 22, 2024 -- Nexalin Technology, Inc. is pleased to announce its new division, Nexalin America, has been selected to join the National Traumatic Brain Injury Registry Coalition ....
HOUSTON, TEXAS, April 25, 2024 -- Nexalin Technology, Inc. announced that the Company received notice from The Nasdaq Stock Market on April 23, 2024, notifying the Company that it has regained...
The new Gen-3 HALO™ Clarity 15 milliamp HOUSTON, TX, April 09, 2024 -- Nexalin Technology, Inc. today announced it has completed the first full production test run and successfully...